Fulgent Genetics to announce Q2 2026 results on July 30

0 min read | Published on 10 Jul 2026, 04:18 AM |Updated on 10 Jul 2026, 04:18 AM

Reviewed by

Anirudha BScanX News Team

Key Highlights

Fulgent Genetics will announce its Q2 2026 financial results on July 30, 2026, followed by a conference call at 4:30 PM ET. The company operates in laboratory services and therapeutic development, targeting precision medicine integration.

*this image is generated using AI for illustrative purposes only.

Fulgent Genetics, Inc. will release its second quarter 2026 financial results after the market closes on Thursday, July 30, 2026. The company, which operates a laboratory services business and a therapeutic development business, scheduled the announcement to provide updates on its performance. Management will host a conference call the same day at 4:30 PM ET to discuss the results and answer questions from the investment community.

Conference Call Details

The conference call will be accessible through a live audio webcast on the Investor Relations section of Fulgent Genetics' website. An audio replay of the call will be available at the same location following the event.

Key Event Information

Event	Date & Time
Q2 2026 Financial Results Release	July 30, 2026 (after market close)
Conference Call	July 30, 2026 at 4:30 PM ET
Webcast Access	http://ir.fulgentgenetics.com

Fulgent Genetics provides technical laboratory and testing services, including professional interpretation of results by licensed physicians. Its therapeutic development business focuses on drug candidates for treating cancers using a nanoencapsulation and targeted therapy platform. The company aims to transition into a fully integrated precision medicine company.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

How will the performance of the nanoencapsulation and targeted therapy platform impact the company's transition to a fully integrated precision medicine model?